共 50 条
- [1] In an open-label clinical study pramlintide lowered A1C, body weight, and insulin use in patients with type 1 diabetes failing to achieve glycemic targets with insulin therapy[J]. DIABETES, 2005, 54 : A118 - A118Guthrie, RKarl, DMWang, YLorenzi, G
- [2] Pramlintide as an adjunct to insulin glargine reduced A1C and body weight in patients with type 2 diabetes[J]. DIABETES, 2006, 55 : A112 - A112Frias, JuanBei, ZhangDarsow, Tamara
- [3] Pramlintide, as an adjunct to premixed insulin, reduced A1C and body weight in patients with type 2 diabetes[J]. DIABETES, 2008, 57 : A585 - A585Lorenzi, GayleZhang, BeiDarsow, TamaraMaier, HollyWilhelm, Ken
- [4] Pramlintide, as an adjunct to long-acting insulin, led to improved A1C and body weight in patients with type 2 diabetes[J]. DIABETES, 2006, 55 : A124 - A124Lush, CameronStrobel, SusanZhang, BeiFrias, Juan
- [5] Adjunctive therapy with pramlintide lowers A1c without concomitant weight gain in patients with type 2 diabetes approaching ADA glycemic targets[J]. DIABETES, 2003, 52 : A138 - A138Weyer, CFineman, MBurrell, TStrobel, SShen, LKolterman, O
- [6] Influence of preprandial vs postprandial insulin glulisine on A1C and body weight in patients with type 2 diabetes mellitus (T2DM) receiving basal insulin therapy: A multicenter, randomized, parallel, open-label study[J]. DIABETES, 2008, 57 : A722 - A722Wynne, Alan G.Nakhle, SamerBrusco, O. A.Rendell, Marc S.Vlajnic, AleksandraRatner, Robert E.
- [7] Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight[J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2007, 9 (02) : 191 - 199Karl, DianePhilis-Tsimikas, AthenaDarsow, TamaraLorenzi, GayleKellmeyer, TerrieLutz, KarenWang, YanFrias, Juan P.
- [8] A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes[J]. DIABETES CARE, 2002, 25 (04) : 724 - 730Whitehouse, FKruger, DFFineman, MShen, LRuggles, JAMaggs, DGWeyer, CKolterman, OG
- [9] Pramlintide improved glycemic control and reduced body weight in patients with type 2 diabetes treated with basal insulin (without mealtime insulin) and a thiazolidinedione[J]. DIABETES, 2007, 56 : A147 - A147Lorenzi, GayleFrias, JuanLutz, KarenKesty, NicoleZhang, BeiKolterman, Orville
- [10] Pramlintide, as an adjunct to premixed insulin, reduced HbA1c and body weight in patients with type 2 diabetes[J]. DIABETOLOGIA, 2008, 51 : S409 - S409Darsow, T.Lorenzi, G.Zhang, B.Maier, H.Wilhelm, K.